Inception Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases. The company's primary focus is on [NLRP3 inflammasome](/entities/nlrp3-inflammasome) inhibitors designed specifically for central nervous system applications, with an initial emphasis on [Parkinson's disease](/diseases/parkinsons-disease).
Company Profile
| Attribute | Value | |-----------|-------| | Founded | 2020 | | Headquarters | San Diego, California, USA | | CEO | Dr. Robert H. Brown | | Funding | Series A ($32M, 2021) | | Focus | CNS NLRP3 inhibitors | | Stage | Preclinical |
Scientific Foundation
Inception Therapeutics was founded by leading neuroscientists from UC San Diego and The Scripps Research Institute:
Scientific founders: Dr. Stuart Lipton (neuroscience), Dr. John Reed (drug discovery)
Focus: Translating basic NLRP3 research into CNS therapeutics
Approach: Brain-specific optimization of NLRP3 inhibitors
The company's name reflects its "inception" concept—starting from the fundamental biology of neuroinflammation to create transformative therapies.
Science and Technology
CNS-Optimized NLRP3 Platform
Inception's platform is specifically designed for brain applications:
BBB penetration: High brain-to-plasma ratios (>0.5)
Microglial targeting: Enhanced activity in activated microglia
Clean safety profile: No peripheral immune suppression
Mechanism in Parkinson's Disease
...
Overview
Inception Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases. The company's primary focus is on [NLRP3 inflammasome](/entities/nlrp3-inflammasome) inhibitors designed specifically for central nervous system applications, with an initial emphasis on [Parkinson's disease](/diseases/parkinsons-disease).
Company Profile
| Attribute | Value | |-----------|-------| | Founded | 2020 | | Headquarters | San Diego, California, USA | | CEO | Dr. Robert H. Brown | | Funding | Series A ($32M, 2021) | | Focus | CNS NLRP3 inhibitors | | Stage | Preclinical |
Scientific Foundation
Inception Therapeutics was founded by leading neuroscientists from UC San Diego and The Scripps Research Institute:
Scientific founders: Dr. Stuart Lipton (neuroscience), Dr. John Reed (drug discovery)
Focus: Translating basic NLRP3 research into CNS therapeutics
Approach: Brain-specific optimization of NLRP3 inhibitors
The company's name reflects its "inception" concept—starting from the fundamental biology of neuroinflammation to create transformative therapies.
Science and Technology
CNS-Optimized NLRP3 Platform
Inception's platform is specifically designed for brain applications:
BBB penetration: High brain-to-plasma ratios (>0.5)
Microglial targeting: Enhanced activity in activated microglia